TransGenex Nanobiotech Inc.
This article was originally published in Start Up
Executive Summary
TransGenex Nanobiotech is taking a multi-pronged approach to building a nanotechnology company. In the short term, the company is generating revenue from sales of its custom nanoparticles and its Nanogene reagents that can be used to deliver genes to cells. It is also using its technology to develop diagnostic platforms, especially for lung and ovarian cancer. Finally, TransGenex plans to develop its own novel drug candidates. It's focusing first on products with anti-inflammatory properties, which could find application in asthma as well as several cancers.
You may also be interested in...
Start-Up Previews (04/2008)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Nanotechnology, a Balm for the Challenges of Drug Delivery," features profiles of BIND Biosciences, Liquidia Technologies, Nanolymf, Tempo Pharmaceuticals, and TransGenex Nanobiotech. Plus these Start-Ups Across Health Care: Breathe Technologies, Crospon, and InterMed Discovery.
Liquidia Technologies Inc.
Liquidia Technologies is developing nanoparticles whose size, shape, particle cargo, and target specificity can be exquisitely controlled. In order to create its particles, Liquidia borrows fabrication methods originally developed by the electronics industry. I
Nanolymf Ltd.
Israeli start-up Nanolymf . believes its technology could be used to create oral versions of some of the biggest intravenous and injectable drugs on today's market, including lipophilic drugs that are not readily bioavailable because of biochemical barriers that block their absorption. Nanolymf's nanoencapsulation technology allows the drug to bypass metabolic filters in the intestine and liver, resulting in increased bioavailability following oral administration.